Ascendis Pharma A/S logo

Ascendis Pharma A/SNASDAQ: ASND

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Denmark

IPO:

28 January 2015

Next earnings report:

07 February 2025

Last dividends:

N/A

Next dividends:

N/A
$7.43 B
-20%vs. 3y high
91%vs. sector
-vs. 3y high
-vs. sector
-68.38
-182%vs. 3y high
1%vs. sector
-98%vs. 3y high
86%vs. sector

Price

after hours | Wed, 20 Nov 2024 21:00:12 GMT
$124.38-$0.06(-0.05%)

Dividend

No data over the past 3 years
$63.61 M$97.53 M
$63.61 M-$109.10 M

Analysts recommendations

Institutional Ownership

ASND Latest News

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript
seekingalpha.com14 November 2024 Sentiment: POSITIVE

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jan Mikkelsen - President & Chief Executive Officer Scott Smith - Executive Vice President & Chief Financial Officer Camilla Harder Hartvig - Head of Global Commercial Operation Joe Kelly - US General Manager Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Yaron Werber - TD Cowen Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Joseph Schwartz - Leerink Partners Vikram Purohit - Morgan Stanley Kelly Shi - Jefferies David Lebowitz - Citigroup Inc. Paul Choi - Goldman Sachs Leland Gershell - Oppenheimer Alexander Thompson - Stifel Operator Good day, and thank you for standing by. Welcome to the Ascendis Pharma Third Quarter Earnings Call.

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
globenewswire.com30 September 2024 Sentiment: POSITIVE

COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD).

Ascendant Resources Approved for EU Sponsored Cutting-Edge Geophysical "Undercover" Program at Its Lagoa Salgada Project
accesswire.com30 September 2024 Sentiment: POSITIVE

Lagoa Salgada selected to participate in the European Union's UNDERCOVER Project to unlock hidden critical mineral deposits at depth using cutting edge Geophysical techniques UNDERCOVER Project will employ Seismic Reflection and Refraction, Magnetotellurics (MT), Gravity and Magnetic Surveys, Electromagnetic (EM) Surveys, and Joint Inversion Techniques to delineate potential deposits of critical minerals at depth The two-year program is fully funded by the EU under its Horizon Program and is expected to commence in Q1 2025 TORONTO, ON / ACCESSWIRE / September 30, 2024 / Ascendant Resources Inc. (TSX:ASND), through its Portuguese subsidiary, Redcorp Empreendimentos Mineiros Lda is pleased to announce its award of EU funding through its participation in the UNDERCOVER project. The project aims to advance mineral exploration by applying state-of-the-art geophysical technologies to uncover hidden mineral deposits at significant depths.

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
globenewswire.com19 September 2024 Sentiment: POSITIVE

COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $150.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 23, 2024, subject to the satisfaction of customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 300,000 ADSs at the public offering price, less the underwriting commissions.

Ascendis Soars on Encouraging Data From Dwarfism Drug Study
zacks.com17 September 2024 Sentiment: POSITIVE

ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?
zacks.com17 September 2024 Sentiment: POSITIVE

Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
benzinga.com16 September 2024 Sentiment: POSITIVE

Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
globenewswire.com11 September 2024 Sentiment: POSITIVE

–   U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults

Ascendis Pharma Takes A Big Price Cut On Skytrofa
seekingalpha.com05 September 2024 Sentiment: NEUTRAL

Shares of Ascendis Pharma are under pressure as the company posted a big Q2 revenue miss, driven by a decision to significantly reduce the net price of Skytrofa. Demand for Skytrofa remains strong and quarterly net sales could go back to new highs in the fourth quarter, if not in Q3 already. Yorvipath's U.S. price is above expectations and could increase long-term sales, but initial uptake and payer pushback need monitoring.

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
benzinga.com04 September 2024 Sentiment: NEGATIVE

Tuesday, Ascendis Pharma A/S ASND reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.

  • 1(current)
  • 2
  • 3

What type of business is Ascendis Pharma A/S?

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

What sector is Ascendis Pharma A/S in?

Ascendis Pharma A/S is in the Healthcare sector

What industry is Ascendis Pharma A/S in?

Ascendis Pharma A/S is in the Biotechnology industry

What country is Ascendis Pharma A/S from?

Ascendis Pharma A/S is headquartered in Denmark

When did Ascendis Pharma A/S go public?

Ascendis Pharma A/S initial public offering (IPO) was on 28 January 2015

What is Ascendis Pharma A/S website?

https://ascendispharma.com

Is Ascendis Pharma A/S in the S&P 500?

No, Ascendis Pharma A/S is not included in the S&P 500 index

Is Ascendis Pharma A/S in the NASDAQ 100?

No, Ascendis Pharma A/S is not included in the NASDAQ 100 index

Is Ascendis Pharma A/S in the Dow Jones?

No, Ascendis Pharma A/S is not included in the Dow Jones index

When was Ascendis Pharma A/S the previous earnings report?

No data

When does Ascendis Pharma A/S earnings report?

The next expected earnings date for Ascendis Pharma A/S is 07 February 2025